Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals focuses on developing and commercializing GI products. It markets linaclotide for irritable bowel syndrome with constipation or chronic idiopathic constipation under LINZESS or CONSTELLA names. The company also develops IW-3300, Apraglutide, and CNP-104 for various conditions. Strategic partnerships exist with AbbVie, AstraZeneca, and Astellas Pharma for linaclotide development and commercialization. Ironwood Pharmaceuticals was formerly Microbia, Inc., changing its name in 2008. The company was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Overview

Sector

Pharmaceutical

Target Price

1.6 USD

Current Price

1.1 USD

Potential

40%

Strengths

With an appreciation Potential of 47.44%, based on our fundamental analysis, it suggests the stock may be undervalued.
The company has high returns. ROIC (34.73%) is higher than the sector mean (14.71%).
EV/EBITDA (6.64) is lower than the sector mean (51.86).
EV/EBIT (6.95) is lower than the sector mean.
Price to free cash flow (1.66) is lower than the sector mean.
Strong EBITDA Margin of 29.26%.

Weaknesses

Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (4.97) is higher than the sector mean.

Key Financial Data

Indicator	Value
PER	205.7
EV/EBITDA	6.7
Price/Free Cash Flow'	1.8
ROIC	34.7%
Net Debt/EBITDA	5.0